3.06
0.00%
+0.00
Ovid Therapeutics Inc stock is currently priced at $3.06, with a 24-hour trading volume of 76,611.
It has seen a +0.00% increased in the last 24 hours and a +0.33% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.05 pivot point. If it approaches the $3.10 resistance level, significant changes may occur.
Previous Close:
$3.06
Open:
$3.09
24h Volume:
76,611
Market Cap:
$217.09M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-4.3714
EPS:
-0.7
Net Cash Flow:
$-45.92M
1W Performance:
+2.00%
1M Performance:
+0.33%
6M Performance:
+2.86%
1Y Performance:
-13.56%
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
646-661-7661
Address
1460 Broadway, Suite 15044, New York, NY
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Dravet Syndrome Treatment Market Looks Ready For Takeoff: Biocodex, Epygenix Therapeutics, Zogenix - Newstrail
Newstrail
Ovid Therapeutics Inc. to Post Q2 2024 Earnings of ($0.25) Per Share, HC Wainwright Forecasts (NASDAQ:OVID) - MarketBeat
MarketBeat
Ovid Therapeutics Inc. to Post Q2 2024 Earnings of ($0.25) Per Share, HC Wainwright Forecasts (NASDAQ:OVID) - MarketBeat
MarketBeat
Ovid Therapeutics Inc. (NASDAQ:OVID) Expected to Earn Q2 2024 Earnings of ($0.25) Per Share - Defense World
Defense World
Brokers Set Expectations for Ovid Therapeutics Inc.'s FY2024 Earnings (NASDAQ:OVID) - Defense World
Defense World
HC Wainwright Reaffirms "Buy" Rating for Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
MarketBeat
Ovid Therapeutics Inc Stock (OVID) Financials Data
Ovid Therapeutics Inc (OVID) Revenue 2024
OVID reported a revenue (TTM) of $391.70 thousand for the quarter ending December 31, 2023.
Ovid Therapeutics Inc (OVID) Net Income 2024
OVID net income (TTM) was -$52.34 million for the quarter ending December 31, 2023, a +3.38% increase year-over-year.
Ovid Therapeutics Inc (OVID) Cash Flow 2024
OVID recorded a free cash flow (TTM) of -$45.92 million for the quarter ending December 31, 2023, a +18.94% increase year-over-year.
Ovid Therapeutics Inc (OVID) Earnings per Share 2024
OVID earnings per share (TTM) was -$0.75 for the quarter ending December 31, 2023, a +2.60% growth year-over-year.
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Cap:
|
Volume (24h):